Hypha Labs, INC 10-Q quarterly reports

Hypha Labs, Inc. details its strategic pivot from cannabis testing to mushroom bioreactor development, reporting a net loss for the quarter ended March 31, 2026.

Hypha Labs, Inc. shifts focus from cannabis testing to mushroom cultivation technology, reporting significant losses and a going concern doubt during its R&D phase.

Hypha Labs, Inc. reported a substantial net loss of $1.98 million for the six months ended March 31, 2025, as it transitions from cannabis testing to developing a mushroom accelerator, raising significant concerns about its ability to continue as a going concern.

Hypha Labs, formerly Digipath, reports its Q1 2025 results, highlighting its transition to bioreactor development and commercialization after selling its cannabis testing lab.

Hypha Labs, formerly Digipath, reports its Q3 2024 results, reflecting the sale of its Digipath Labs subsidiary and a shift in business focus.

Hypha Labs, formerly Digipath, reports its Q2 2024 results, highlighting the completion of the sale of its Digipath Labs assets and a shift in business focus.

Digipath Inc. reports a net income of $151,646 for the quarter ended December 31, 2023, driven by discontinued operations, and secures approval for the sale of its lab assets.